INOVIO Announces Pricing of $20.0 Million Public Offering

The brief

INOVIO Pharmaceuticals, Inc. has announced the pricing of a $20.0 million public offering. The biotechnology company, listed on Nasdaq under the ticker symbol INO, focuses on developing and commercializing DNA medicines. The offering is part of INOVIO's efforts to advance its pipeline of treatments for various diseases. The company aims to utilize the funds raised from the public offering to support its ongoing research and development activities. The offering is expected to contribute to INOVIO's growth and expansion in the biotechnology sector.

Auto-summarised from the full article